Vogel, A., Borbath, I., Chiluveru, S., Chon, H. J., Feng, Y., Irahara, N., Kim, B. H., Knox, J. J., Kudo, M., Li, S., Meyer, T., Park, J., Qin, S., Tahiri, A., Touchefeu, Y., Sangro, B. (2026). IMbrave251: Final analysis of atezolizumab (atezo) + lenvatinib (lenva) or sorafenib (sora) vs lenva or sora alone in locally advanced or metastatic hepatocellular carcinoma (LA/mHCC) previously treated with atezo and bevacizumab (bev).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4002